S-217622
Payments companies reported to CMS as associated with S-217622. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with S-217622, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with S-217622
These are the largest totals companies reported as associated with S-217622. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Frederick Hayden | Charlottesville, VA | Infectious Disease | $9,190.40 |
| Walter Kaufmann | Baltimore, MD | Neurodevelopmental Disabilities (Psychiatry & Neurology) | $4,880.00 |
| Stefan Gravenstein | Norfolk, VA | Geriatric Medicine (Family Medicine) | $4,410.00 |
| Kelly Gebo | Baltimore, MD | Internal Medicine | $4,410.00 |
| Amesh Adalja | Pittsburgh, PA | Infectious Disease | $3,881.25 |
| Paul Sax | Boston, MA | Infectious Disease | $3,780.00 |
| Paul Auwaerter | Lutherville, MD | Infectious Disease | $3,780.00 |
| Roger Bedimo | Dallas, TX | Infectious Disease | $3,324.82 |
| Lauren Meyers | Chicago, IL | Pediatrics (Nurse Practitioner) | $3,250.00 |
| David Smith | San Diego, CA | Infectious Disease | $3,182.00 |
Prescribed S-217622?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.